Targeted alpha therapy of NETs using somatostatin-based radiopharmaceuticals with improved tumor-to-kidney ratio, the theranostic approach.
Prof. Dr. Apr. Frederik Cleeren
Finished Projects
Targeting Angiopoietin-2 to Improve ICI Therapy Efficacy in pNET Metastasis
Minah Kim, PhD
Targeting serotonin metabolism in SBNETs
Po Hien Ear, PhD
Targeting the Alternative Lengthening of Telomere (ALT) pathway in pancreatic NETs
Christopher Heaphy, PhD
The impact of MEN1, DAXX, ATRX, and PTEN in pancreatic neuroendocrine cancer pathogenesis
Kwok-Kin Wong, MD, PhD
The mechanistic underpinnings of pancreatic NETs
Guillermina Lozano, PhD
The mechanistic underpinnings of pancreatic NETs
Guillermina Lozano, PhD
The role of ATRX/DAXX/H3.3 chromatin regulation in pancreatic neuroendocrine tumors
Laura Banaszynski, PhD
The role of the B7x pathway in the progression of NETs
Steven K Libutti, MD
Theranostics of NETs with somatostatin antagonists
Wolfgang Weber, MD, PhD; Diane Reidy-Lagunes, MD